Ariana Pharma develops innovative clinical data analysis and diagnostic testing solutions to help the healthcare sector better adapt patient treatments to individual biological characteristics.

Ariana Pharma’s KEM® technology enables personalization of therapies, improves the efficacy and safety of patient treatment, reduces risks and drug development costs, and accelerates time to market. KEM® is the only FDA tested technology that systematically explores combinations of biomarkers, producing more effective biomarker signatures for personalized medicine.

Founded in 2003 as a spin-off of the Institut Pasteur, Paris, France, the company opened a subsidiary in the United States in 2012.

Speakers and Panelists